期刊文献+

同型半胱氨酸与缺血性心肌病和扩张性心肌病的关系探讨 被引量:6

Distinctive relation of serum homocysteine in patients with ischemic cardiomyopathy and dilated cardiomyopathy
下载PDF
导出
摘要 目的:探讨同型半胱氨酸(Hcy)水平变化与缺血性心肌病和扩张性心肌病的关系及意义。方法:选取我院冠心病患者198例,其中缺血性心肌病患者80例(A组),扩张性心肌病患者53例(B组),普通冠心病患者65例(对照组),入选者均行冠状动脉造影。比较三组的一般临床资料。采用酶联免疫法测定并比较三组血清同型半胱氨酸水平,测定相关生化指标。采用彩色多普勒超声诊断仪测定三组左房内径,左室舒末内径及左室射血分数。结果:B组与对照组相比,同型半胱氨酸水平无明显差异,A组同型半胱氨酸水平明显高于对照组(P<0.05),A组同型半胱氨酸水平与B组相比显著增高(P<0.05),A组年龄高于B组及正常对照组(P<0.05)。三组一般临床资料,如糖尿病、血脂、高血压、吸烟饮酒、叶酸、维生素B12水平等方面比较,差异无统计学意义。与对照组相比,A组与B组的左房内径、左室舒末内径明显增大(P<0.05),左室射血分数明显降低(P<0.05)。结论:检测同型半胱氨酸水平在临床上可对鉴别缺血性心肌病和扩张性心肌病提供帮助。 Objective: To study the distinctive relation of changes of level of serum homocysteine(Hcy) in patients with ischemic cardiomyopathy(ICM) and dilated cardiomyopathy(DCM).Methods: 80 patients with ICM was selected as group A,53 patients with DCM was selected as group B,65 normal cases were selected as control group.Clinical data′s of 3 groups were compared.Hcy of 3 groups were analyzed by enzymoimmunoassay(MAIA),and biochemical indexes were assayed.Left atrial dimension(LAD),left ventricular enddiastolic dimension,left ventricular ejection fraction were assayed by diasonograph.Results: There was no difference at Hcy between group B and control group,Hcy of group A was significantly higher than control group(P0.05),Hcy of group A was significantly higher than group B(P0.05).The age of group A was higher than group B and control group(P0.05).There were no difference in clinic dates of 3 groups included smoking,drinking,fat,diabetes,hypertension,folate,Vitamin B12 and so on.LAD and left ventricular enddiastolic dimension of group A and group B were increased than control group(P0.05).Left ventricular ejection fraction were obviously decrease than control group(P0.05).Conclusion: Hcy level may help to distinguish DCM and ICM in clinic.
作者 杨萃 张月兰
机构地区 中国医科大学
出处 《中国医药导报》 CAS 2011年第16期36-38,共3页 China Medical Herald
关键词 缺血性心肌病 扩张性心肌病 同型半胱氨酸 冠心病 Ischemic Cardiomyopathy(ICM) Dilated cardiomyopathy(DCM) Homocysteine(Hcy) Coronary heart disease(CHD)
  • 相关文献

参考文献9

  • 1Mendis S, Ranatunga P, Jayatilake M, et al. Hyperhomocysteinaemia in Sri Lan-kan patients with coronary artery disease [J]. NCeylon Med J, 2002,47(3):89-92.
  • 2李轶,耿辉,宋丽晶.血浆同型半胱氨酸浓度与冠心病发病的相关性研究[J].中国医药导报,2009,6(14):91-91. 被引量:4
  • 3范伯丽,程颖,房家智,Brian Tomlinson.同型半胱氨酸作用于正常个体血小板凝聚反应的体外研究[J].中国心血管杂志,2003,8(4):243-246. 被引量:4
  • 4Vizzardi E, Nodari S, Fiofina C, et al. Plasma homocysteine levels and late outcome in patients with unstable angine [J]. Cardiology,2007,107 (4):354-359.
  • 5Munshi MN, Stone A, Fink L, et al. Hyperhomocysteinemia following a methionine load in patients with non-insulin dependent diabies mellitus and macrovascular disease [J]. Metabolism,2006,45(1):133-136.
  • 6Alam MA, Hasain SA, Narang R, et al. Association of polymorphism in the thermolabile 5, 10-methylene tetrahydrofolate reductase gene and hyperhomocysteinemia with coronary artery disease [J]. Mol Cell Biochem,2008,310( 1-2): 111-117.
  • 7Guido Schnyder MD, Riccardo Pin, Marco Roffi MD, et al. Association of plasma homocysteine with the number of major coronary arteries severely roan'owed [J]. AM J Cardiol,2001,89(9):1027.
  • 8Lenzen H, Tslkas D, Boger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study [J]. Eur J Clin Pharmacol,2006,62(Suppl 13):45-49.
  • 9Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter coronary artery risk determination investigating the influence of ADMA concentration (CARDIAC) study [J]. Am Heart J, 2006.152(3):493.

二级参考文献12

  • 1Ueland PM,Refsum H,Stabler SP,et al.Total homocysteine in plasma of serum:Methods and clinical applications[J].Clin Chem,1993,39(9):1764-1769.
  • 2Jacobsen DW,Gatautis VJ,Green R,et al.Rapid HPLC determination of tatal homocysteine and other thiof in serum and plasma:sex different and correlation with cobafamin and folate concentration in health subjects[J].Clin Chem,1994,40(5):873-882.
  • 3Bouskey CJ.A quatitative assessment of plasma homocysteine as a risk factor for vascular disease[J].JAMA,1995,274:1049.
  • 4Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis[J]. Thromb Res, 1993,71 : 337-359.
  • 5Lolin YI, Sanderson JE, Cheng SK, et al. Hyperhomocysteinaemia and premature oronary artery disease in the Chinese[J]. Heart,1996,76:l17-122.
  • 6Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst (e)inemia in humans[J]. Circulation, 1999,100 : 1161-1168.
  • 7BellamyMF, McDowell IF, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults[J]. Circulation, 1998,98: 1848-1852.
  • 8Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cells growth by homocysteine: a link to atherosclerosis[J]. Proc Natl Acad Sci USA, 1994,91 : 6369-6373.
  • 9Nishio E, Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide[J]. Brit J Pharmacol, 1997,122 : 269-274.
  • 10Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis[J]. J Nutr, 1996,126 : 1285S-1289S.

共引文献6

同被引文献44

  • 1王付彬.C-反应蛋白水平与急性心肌梗死预后的关系[J].中国心血管病研究,2005,3(4):294-295. 被引量:13
  • 2宋治远.缺血性心肌病的诊断和鉴别诊断[J].中国医师进修杂志(内科版),2006,29(10):1-3. 被引量:12
  • 3Niccoli G,Conte M,Bone RD,et al. Cystatin C is associated with atheroscle- rotic burden and a stable plaque phenotype in patients with ischenormal glomerular filtration rate [J]. Atherosclerosis, 2008,198(2):373-380.
  • 4Yeh ET, Willerson JT. Coming of age of ereaetive protein:Using inflam- mation markers in cardiology [J]. Circulation , 2003, 107(3):370- 371.
  • 5Nagesh CM,Roy A. Role of biomarkers in risk stratification of acute corn- nary syndrome[J]. Indian J Med Res, 2010, 132(5): 627-633.
  • 6Ix JH,Shlipak MG,Chertow GM,et al. Association of cystatin C with mor- tality,cardiovascular events and incident heart failure among persons with coronary heart disease: Data from the heart at-d soul study[J]. Cir- culation, 2007, 115 (2):173-179.
  • 7Tenenbaum A, Fisman EZ, Motro M. Toward a redefinition of is- chemiccardiomyopathy :is it all indivisible entity [J]. J Am Coil Cardio 1,2002,40 ( 1 ) : 205 -206.
  • 8Mendis S, Ranatunga P, Jayatilake M, et al. Hyperhomocystein- aemia inSri Lan-kan patients with coronary artery disease [J]. Ceylon Med J, 2002,47 (3) : 89-92.
  • 9Moreno R, ovidio AD, Zamorano J, et al. Distinguishing between ischemic and non--ischemic dilated cardiomyopathy based on non-invasive ultrasonic evaluation of peripheral arteries[J]. Eur J Intern Med, 2005,16 ( 1 ) : 41-46.
  • 10Joshi MS, Tong L, Cook AC, et al. Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival[J]. Cardiovasc Pathol, 2012, 21(5) : 428-435.

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部